Compare BGC & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | MANE |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.3B |
| IPO Year | 1999 | 2026 |
| Metric | BGC | MANE |
|---|---|---|
| Price | $11.59 | $116.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.50 | ★ $163.50 |
| AVG Volume (30 Days) | ★ 2.6M | 583.3K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 24.00 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $2,941,460,000.00 | N/A |
| Revenue This Year | $22.84 | N/A |
| Revenue Next Year | $6.44 | N/A |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 29.99 | N/A |
| 52 Week Low | $8.27 | $36.26 |
| 52 Week High | $12.89 | $131.24 |
| Indicator | BGC | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 68.48 |
| Support Level | $10.13 | $92.62 |
| Resistance Level | $11.85 | $130.52 |
| Average True Range (ATR) | 0.35 | 5.98 |
| MACD | -0.12 | 1.76 |
| Stochastic Oscillator | 18.73 | 98.37 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, the Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.